VLDLR and cancer: We treated cancer cells with GST-RAP fusion protein and found that cell proliferation promoted by VLDLR-I and VLDLR-II overexpression was not affected (Figure 4A), suggesting that the ligand binding activity was not involved in the cancer-promoting function of VLDLR.